# INVIVYD, INC. (IVVD) · Edgar & Edgarette company card

> Invivyd (IVVD) grew revenue 110% in FY2025 to $53 million, operating margin -104% against a -15.8% median for biological products, (no diagnostic substances), equity 87.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1832038 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/IVVD) · [JSON](https://www.pops4.com/boards/company/IVVD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $53M |
| Revenue growth, 1 year | 110.5% |
| Revenue growth per year | — |
| Operating margin | -104.0% (prior year -696.8%) |
| Net margin | -98.2% |
| Operating cash flow | −$58M |
| Capital spending | $155,000 |
| Free cash flow | −$58M |
| Cash | $227M |
| Long-term debt | — |
| Total assets | $277M |
| Total equity | $242M |
| Equity ÷ assets | 87.2% |
| Return on equity | -21.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -0.36 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -104.0% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $53.4M (FY2025). Experience: revenue up 110.5% on the year; operating margin -104.0%, up from -696.8%. Soundness: equity 87.2% of assets, return on equity -21.7%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $82.5M and $148.2M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -104.0% against a -15.8% median; growth 110.5% against 21.4%.

Range logged 2026-10-09, receipt 9f0dda5c3381b02a, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-07-24 ([filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526316066/0001193125-26-316066-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-09-01 ([filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526377493/0001193125-26-377493-index.htm))

## Recent filings

- 10-Q · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526462034/0001193125-26-462034-index.htm)
- 8-K · filed 2026-11-16 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526462025/0001193125-26-462025-index.htm)
- 8-K · filed 2026-09-29 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526406007/0001193125-26-406007-index.htm)
- 8-K · filed 2026-09-01 · 5.02 Departure or Election of Directors; Appointment of Officers; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526377493/0001193125-26-377493-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349215/0001193125-26-349215-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/0001193125-26-349193-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001832038.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1832038

## Cite

POPS4, Edgar & Edgarette: INVIVYD, INC. (IVVD) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/IVVD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

